The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas
International Journal of Clinical Practice2009Vol. 63(3), pp. 368–375
Citations Over TimeTop 10% of 2009 papers
Peter Pertel, Barry I. Eisenstein, Arthur S. Link, B Donfrid, Elmar Biermann, Patricia Bernardo, W. J. Martone
Abstract
There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin. Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas.
Related Papers
- → Analysis of Complications From Abdominoplasty(2007)249 cited
- → Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes(2007)86 cited
- Cellulitis and erysipelas.(2002)
- → The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas(2009)57 cited
- → Modulation of inflammatory mediators during treatment of cellulitis with daptomycin or vancomycin/oxacillin(2015)4 cited